Upstream Processing: Regulatory Considerations Regarding Quality Aspects of Monoclonal Antibodies - An alternative to the hybridoma method is producing engineered antibody molecules and fragments

ADVERTISEMENT

Upstream Processing: Regulatory Considerations Regarding Quality Aspects of Monoclonal Antibodies
An alternative to the hybridoma method is producing engineered antibody molecules and fragments by in vitro methods.


BioPharm International
Volume 20, Issue 7

16. http:// http://www.fda.gov/cber/gdlns/vaccsubstrates.pdf [Accessed 2006;Dec 29].

17. http:// http://www.emea.europa.eu/pdfs/human/ich/013895en.pdf [Accessed 2005;Oct 3].

18. Marcus-Sekura CJ, Kozak RW. Continuous cell lines and contaminant testing in novel therapeutics. In: Modern biotechnology: from laboratory to human testing, (Oxender DL and LE Post, eds.) London: Springer-Verlag; 1999.

19. http:// http://www.actip.org/manuals/libraryfiles/safety.html [Accessed 2005;Sept 12].

20. Ford S, Tente WE. Employing murine MAbs as ancillary products in cell therapy manufacturing: part1. BioPharm 2001;10-14.

21. Ford S, Tente WE. Employing murine MAbs as ancillary products in cell therapy: part 2: a case study. BioPharm 2001;16-26.

22. Quality of biotechnology products: analysis of the expression construct in cells used for production of rDNA-derived protein products. http:// http://www.ich.org/LOB/media/MEDIA426.pdf [Accessed 2005;Sept 15].

23. Tsang L. Regulatory and legal requirements for the manufacture of antibodies. In: Antibodies, Vol. 1: Production and purification (Subramanian G, ed.) New York: Kluwer Academic/Plenum Publishers; 2004.

24. Comparability of biotechnological/biological products subject to changes in their manufacturing process. http:// http://www.ich.org/LOB/media/MEDIA1196.pdf [Accessed 2006;Oct 12].

25. http:// http://www3.niaid.nih.gov/research/topics/HIV/vaccines/reports/PDF/Whiteman.pdf [Accessed 2006;Sept 12].

26. Shepard AJ, Wilson NJ, Smith KT. Characterization of endogenus retrovirus in rodent cell lines used for production in biologicals. Biologicals 2003;31:251-260.

27. Jacob LR, Frech M. Scale up of antibody purification. In: Antibodies Vol. 1: Production and purification (Subramanian G, ed.) New York: Kluwer Academic/Plenum Publishers; 2004.

28. http:// http://www.ich.org/LOB/media/MEDIA425.pdf [Accessed 2005;Aug 25].

29. http:// http://www.emea.europa.eu/pdfs/human/bwp/026895en.pdf [Accessed 2005;Aug 25].

30. http:// http://www.bioreliance.com/pdfs/Literature/quantPCR_residDNA.pdf [Accessed 2005 Sept 5].

31. http:// http://www.who.int/biologicals/publications/trs/areas/vaccines/cells/WHO_TRS_878_A1Animalcells.pdf [Accessed 2005 Oct 3].

32. http:// http://www.casss.org/cmc/PDFs/2005SEP_Bio-Process_Part2.pdf [Accessed 2005 Sept 22].

33. Q-One Biotech: Safety testing strategy for CHO or BHK cells where the product is intended for human use. Q-One biotech testing schedule. March 2002: No. 3.

34. http:// http://www.emea.eu.int/humandocs/Humans/EPAR/Remicade/Remicade.htm [Accessed 2005 Oct 15].


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

NIH Launches Human Safety Study of Ebola Vaccine Candidate
August 29, 2014
Suppliers Seek to Boost Single-Use Technology
August 21, 2014
Bristol-Myers Squibb and Celgene Collaborate on Immunotherapy and Chemotherapy Combination Regimen
August 20, 2014
FDA Warns about Fraudulent Ebola Treatments
August 15, 2014
USP Awards Analytical Research
August 15, 2014
Author Guidelines
Source: BioPharm International,
Click here